Fig. 4. Receiver operating characteristic curve for discriminating PCa from BPH controls in the validation cohort. (A) All patients. (B) Patients within the PSA gray zone (3–10 ng/mL). AUC, area under the curve; BPH, benign prostate hyperplasia; CI, confidence interval; PCa, prostate cancer; PSA, prostate-specific antigen. ^*A p-value was determined by the Z-score.